共 20 条
- [1] Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastomaNEURO-ONCOLOGY ADVANCES, 2024, 6 (01)Holdhoff, MatthiasYe, XiaobuStrowd, Roy E.Nabors, BurtWalbert, TobiasLieberman, Frank S.Bagley, Stephen J.Fiveash, John B.Fisher, Joy D.Desideri, SerenaSurakus, TrishaEngelhardt, MarcKaindl, ThomasLane, Heidi A.Litherland, KarineGrossman, Stuart A.Kleinberg, Lawrence R.
- [2] The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Tiu, Crescens DianeDerby, SarahHaris, Noor MdWelsh, LiamStansfeld, AnnaHundsberger, ThomasRoth, PatrickKonig, FatimaEisner, Joel RobertKleinschmidt, MalteAnderson, StephanieBachmann, FelixLane, Heidi A.Engelhardt, MarcKaindl, ThomasLitherland, KarineStan, Alexandru C.Evans, T. R. JeffryPlummer, Elizabeth RuthLopez, Juanita Suzanne
- [3] Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Lopez, Juanita SuzannePlummer, Elizabeth RuthDevlin, Michael-JohnRulach, RobertGarces, Alvaro Henrique InglesHaris, Noor R. MdMiller, RowanCrawford, DonnaD'Arcangelo, ManoloAversa, CaterinaHannah, Alison L.Anderson, StephanieEngelhardt, Marc FrederickKaindl, ThomasLarger, PatriceBachmann, FelixLane, Heidi A.McKernan, PhilEvans, T. R. JeffryKristeleit, Rebecca Sophie
- [4] PHASE 1/2 STUDY OF DIANHYDROGALACTITOL (VAL-083) WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMANEURO-ONCOLOGY, 2018, 20 : 27 - 27Chen, Zhong-pingGuo, ChengchengBacha, JeffreySteino, AnneLanglands, JohnKwan, ClaireKanekal, SarathSchwartz, RichardLopez, LorenaBrown, Dennis
- [5] The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)ANNALS OF ONCOLOGY, 2020, 31 : S404 - S404Tiu, C.Tzankov, A.Plummer, R.Rulach, R.Vivanco, I.Mulholland, P. J.Gurel, B.Figueiredo, I.Haris, N. Md.Anderson, S.Bachmann, F.Engelhardt, M.Kaindl, T.Lane, H.Litherland, K.Pognan, C.Berezowska, S.Evans, J.Kristeleit, R.Lopez, J. S.
- [6] Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Lopez, Juanita SuzanneKristeleit, Rebecca SophieRulach, RobertHaris, Noor MdScaranti, MarianaMulholland, Paul JamesCrawford, DonnaBashir, SairaAversa, CaterinaHannah, Alison L.Anderson, StephanieEngelhardt, MarcKaindl, ThomasLarger, PatriceMcKernan, PhilEvans, T. R. JeffryPlummer, Elizabeth
- [7] A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patientsCANCER RESEARCH, 2024, 84 (07)Sanai, NaderDesai, SiddhiMargaryan, TigranMolloy, JenniferLoCascio, CostanzaElliott, MackennaHarmon, JocelynHong, AmyMelendez, Ernesto LunaWanebo, JohnBraun, KellyKennedy, WilliamGarcia, MichaelYoo, WonsukTovmasyan, ArtakTien, An-ChiMehta, Shwetal
- [8] A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN NEWLY DIAGNOSED, MGMT-UNMETHYLATED AND RECURRENT GLIOBLASTOMA PATIENTSNEURO-ONCOLOGY, 2024, 26Sanai, NaderUmemura, YoshieDesai, SiddhiMargaryan, TigranMolloy, JenniferLocascio, CostanzaElliott, MackennaHarmon, JocelynHong, AmyMelendez, Ernesto LunaWanebo, JohnBraun, KellyKennedy, William R.Garcia, MichaelYoo, WonsukTovmasyan, ArtakTien, An-ChiMehta, Shwetal
- [9] A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumorsInvestigational New Drugs, 2020, 38 : 1067 - 1076Markus JoergerAnastasios StathisYannis MetaxasDagmar HessMara MantieroMichael MarkMatthias VoldenThomas KaindlMarc EngelhardtPatrice LargerHeidi LanePeter HafnerNicole LevySilvia StuedeliCristiana SessaRoger von Moos
- [10] A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1067 - 1076Joerger, MarkusStathis, AnastasiosMetaxas, YannisHess, DagmarMantiero, MaraMark, MichaelVolden, MatthiasKaindl, ThomasEngelhardt, MarcLarger, PatriceLane, HeidiHafner, PeterLevy, NicoleStuedeli, SilviaSessa, Cristianavon Moos, Roger